Research programme: adoptive T-cell therapy - MedigeneAlternative Names: Immunotherapy-Medigene Immunotherapies; TCR-modified T-cells-Medigene Immunotherapies
Latest Information Update: 19 May 2016
At a glance
- Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
- Developer Medigene Immunotherapies
- Class Cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer